Ryvu Therapeutics SA

RVU · GPW

Public Market Listing

RVUGPW

GPW primary exchange listing

Live quotes, historical charts, and market capitalization for Ryvu Therapeutics SA are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
CDK8 / CDK19Small molecule
Acute Myeloid Leukemia

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
RomaciclibPhase 2Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
Est. primary completion 2026-12 · NCT06987058 · CT.gov ↗
What to watch
2027 (1)
August 2027 (1)
RomaciclibPhase 2Acute Myeloid Leukemia
Est. primary completion 2027-08 · NCT06191263 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (3)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$17M$39M$25M$23Mreport ↗

Ryvu Therapeutics SA reported revenue of $17.01M, R&D spend of $38.97M, cash and equivalents of $24.52M, and a net loss of $22.98M for Q3 2025.

Figures only: this period's report disclosed no narrative text

View 2 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$11M$25M$30M$7.6Mreport ↗
2025-Q1$5.3M$12M$39M$6.3Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$23M$48M$17M—report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$26M$55M$39M—report ↗
2023-FY$16M$37M$15M—report ↗
2022-FY$15M$26M$23M—report ↗
2021-FY$9.2M$24M$21M—report ↗